Aditxt, Inc.

ADTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021
Revenue $3.2K $134.0K $645.2K $933.7K $105.0K
Cost of Revenue $2.9K $627.5K $756.8K $766.8K $78.0K
Gross Profit $268 $-493.5K $-111.7K $166.9K $27.1K
Gross Margin 8.4% -368.3% -17.3% 17.9% 25.8%
Operating Expenses
Research & Development $3.2M $10.9M $7.1M $7.3M $5.0M
SG&A Expense $16.0M $16.3M $18.6M $1.8M $335.0K
Operating Income $-19.6M $-27.9M $-26.1M $-25.5M $-41.9M
Operating Margin -612,542.2% -20,796.1% -4,039.6% -2,728.9% -39,925.1%
Interest Expense $0 $15.8K
Pretax Income $-42.8M $-35.0M $-32.4M $-27.6M $-46.4M
Income Tax Expense
Net Income $-43.1M $-40.4M $-32.7M $-27.6M $-46.4M
Net Margin -1,349,028.2% -30,117.9% -5,068.5% -2,961.3% -44,148.9%
EPS (Basic) $-1,153.83 $-7,382,471.74 $-9,012.75 $-28.43 $-5.77
EPS (Diluted) $-1,153.83 $-7,382,471.74 $-9,012.75 $-28.36 $-5.77
Shares Outstanding (Basic) 37.4K 39.5K 907.1K 973.7K 8.0M
Shares Outstanding (Diluted) 37.4K 39.5K 907.1K 973.7K 8.0M
Dividends Per Share